What’s new

Cancer Survivorship: Tackling the Long-Term Side Effects of Treatment

One in two of us will be diagnosed with some form of cancer in our lives. The good news is

Read More

OCB Launches ToxNav in the UK Market

Oxford Cancer Biomarkers launches ToxNav to improve morbidity and mortality rates in patients undergoing CRC chemotherapy   Oxford, UK, 28

Read More

OCB present ToxNav on ESMO-GI 2018

ESMO World Congress on Gastrointestinal Cancer Barcelona, Spain 20-23 Jun 2018 At ESMO-GI on 22nd June 2018 OCB was pleased

Read More

MBM and OCB launch ColoProg in China on March 7th 2018

Oxford developed prognostic assay for risk of post-surgical recurrence in Stage II colorectal cancer patients to be available throughout China

Read More

Oxford Cancer Biomarkers appoints David Browning as its Chief Executive Officer and Board member

Oxford, UK, 9th October 2017 Oxford Cancer Biomarkers has appointed healthcare industry leader David Browning as Chief Executive Officer and

Read More

MBM and OCB announce the set-up of joint laboratories in Ningbo Meishan and Oxford at the 3rd China Medical Devices Int’l Summit on 26th August 2017

Oxford, UK, 1st September 2017 The announcement, at the 3rd China Medical Devices Int’l Summit, follows the signing in March

Read More

Oxford Cancer Biomarkers welcomes major investment partnership with MGMED, Inc.

Investment will drive rapid uptake of OCB’s cancer tests and expand its development pipeline Oxford Cancer Biomarkers Ltd (OCB), the

Read More

Oxford Cancer Biomarkers announces strategic collaboration with My-BioMed Biotechnology Co. Ltd

Collaboration will allow OCB’s suite of precision oncology In Vitro Diagnostic tests to be rolled out across the People’s Republic

Read More